Glenmark Pharmaceuticals Ltd., an India-based, global pharmaceutical company, announced on Tuesday that Glenmark Pharmaceuticals Inc., USA, a fully owned subsidiary of Glenmark Pharmaceuticals Ltd, has acquired the approved Abbreviated New Drug Applications (ANDAs) for Famotidine Tablets USP, 10mg and 20mg (OTC), Cetirizine Hydrochloride Tablets USP, 5mg and 10mg (OTC), Lansoprazole Delayed-Release Capsules USP, 15mg (OTC) and Olopatadine Hydrochloride Ophthalmic Solution USP, 0.1% (OTC) in the United States from India-based Wockhardt Limited.

Glenmark's present range includes 175 products authorised for distribution in the United States marketplace and 48 ANDAs pending approval with the United States FDA. The company is also continuing to identify and explore external development partnerships to supplement and expedite the growth of its present pipeline and portfolio.

Sanjeev Krishan, Glenmark Pharmaceuticals Inc., USA president, said, 'The over-the-counter market has long been an important segment of Glenmark's portfolio around the world. Our acquisition of these ANDAs represents the continued expansion of our business into the OTC market here in the United States and our commitment to ensuring patients have access to high quality, affordable medicines.'